Editorial Staff

  • Clinical Editor:

    Morton Kern, MD
  • Executive Editor:

    Laurie Gustafson
  • Managing Editor:

    Rebecca Kapur
  • Production Manager:

    Elizabeth Vasil
  • Editorial Correspondence

  • Rebecca Kapur, Managing Editor, Cath Lab Digest
  • HMP Communications, 83 General Warren Blvd

    Suite 100, Malvern PA 19355
  • Telephone: (800) 459-8657

    Fax: (866) 896-8762
  • Email: rkapur@hmpcommunications.com
  • December, 2006
    Volume 14
    Issue 12

    Morton Kern, MD, Clinical Editor, Clinical Professor of Medicine, Associate Chief Cardiology, University of California Irvine,
    Orange, California

    The year has also provided us with more information about how best to manage myocardial infarction beyond door-to-balloon time both directly and through improved pharmacology. The prevention of renal dysfunction during interventional studies remains of high interest in our field.

    Let's start with the downside of DES. To reiterate, the biggest advance in the invasive treatment of coronary artery disease in the last decade is the drug-eluting stent. DES lowered the stent-related restenosis rate and remains highly effective for treating a variety of complex lesions. However, the downside o

    continue reading
    Volume 14 - Issue 12 - December, 2006   |   2,097 reads

    Patricia Bailey, RN, BSN, Cardiac Cath/EP Lab Manager, Huntsville, Alabama

    What type of procedures are performed at your facility?

    A variety of procedures are performed on approximately 125 adult patients per week. Procedures include angioplasty, stenting, AngioJet® thrombectomy (Possis Medical, Inc., Minneapolis, MN) and Export Aspiration Catheter (Medtronic, Minneapolis, MN), iLab Intravascular Ultrasound (IVUS) (Boston Scientific, Maple Grove, MN), FilterWire (Boston Scientific, Natick, MA), PolarCath (CryoVascular Systems, Inc./Boston Scientific), SmartWire Pressure System (Volcano Therapeutics, Inc., Rancho Cordova, CA), directional coronary atherecto

    continue reading
    Volume 14 - Issue 12 - December, 2006   |   11,357 reads

    Ramon Quesada, MD, Medical Director of Interventional Cardiology at Baptist Cardiac and Vascular Institute, Miami, Florida and ISET Course Director

    To be fair, pediatric interventional cardiologists began paving the way in the 1990s with endovascular repair of congenital heart defects, but the field is expanding to include adult patients. Interestingly, some adults who have had surgical repair of their congenital heart defects as infants or children repair that often can now be done percutaneously are now in need of revision, which in some cases can be done endovascularly.

    Structural heart disease itself is a bit of an ambiguous umbrella term for any condition related to the heart and major arteries, rather than the smaller blood ves

    continue reading
    Volume 14 - Issue 12 - December, 2006   |   7,035 reads

    Cath Lab Digest talks with J. Tift Mann III, MD, FACC, Wake Heart and Vascular Associates, Raleigh, North Carolina, about his experience with transradial access and a new simulator to enhance the skills of novel transradial operators.

    The most important thing has been the consistent reports of the positive benefits for patients undergoing transradial procedures. Interventional tools are getting smaller, and virtually all of the procedures interventionalists perform can now be done transradially. Previously the need for smaller catheters was a limitation to the technique; the radial artery is obviously smaller than the femoral artery. But now there really are no technical disadvantages when you go to transradial access.

    Another important development is that the honeymoon period for femoral closure devices is now over. P

    continue reading
    Volume 14 - Issue 12 - December, 2006   |   4,711 reads

    By Timothy P. Grady, DO, FACC

    Can you describe the TC-WYRE study?

    The TC-WYRE (TAXUS® Stent-Cypher® Stent What's Your Real World Experience) study is a large, retrospective clinical evaluation of one-year outcomes among 1,558 patients who received either a TAXUS Stent or Cypher Stent at 19 centers throughout the United States. TC-WYRE is a real-world study of drug-eluting stents (DES). In other words, it evaluated the real, complex, diverse patient population we treat every day in our cath labs. The primary endpoint of the study was target vessel revascularization (TVR) at one year. This study is sponsored by B

    continue reading
    Volume 14 - Issue 12 - December, 2006   |   1,966 reads